Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label AASLD 2016 Meeting. Show all posts
Showing posts with label AASLD 2016 Meeting. Show all posts
Monday, January 2, 2017

2016/2017 - New HCV two and three drug regimens on their way: what do they promise?

›
Summary for AASLD 2016 for Hepatitis C - New HCV two and three drug regimens on their way: what do they promise? And what do clinicians need...
Monday, December 26, 2016

Hepatitis C - Screening for HCC in the Post-SVR12 Setting

›
2018 - Updates Letter to the editor Jan 2018 Hepatocellular Carcinoma Screening in Patients Treated for Hepatitis C SVR Reduced ...
Thursday, December 22, 2016

Generic Sofosbuvir Underperforms in Real World, May Be Due to Suboptimal Regimens

›
AASLD 2016: Generic Sofosbuvir Underperforms in Real World, May Be Due to Suboptimal Regimens HCV Treatment Published on Thursday, 15 D...
Wednesday, November 30, 2016

VIDEO: Don’t be surprised by weight gain in men after HCV cure

›
VIDEO: Don’t be surprised by weight gain in men after HCV cure Publish date: November 15, 2016 By: Kari Oakes Frontline Medical News ...
Tuesday, November 22, 2016

(Epclusa) Sofosbuvir plus velpatasvir “best options” for HCV G3

›
Related Epclusa for Hep C: What Pharmacists Should Know JANUARY 04, 2017 Hepatitis C is an infection of the liver caused by the hepat...
Saturday, November 19, 2016

VIDEO: Cost to treat HCV could be as low as $80 in the US

›
VIDEO: Cost to treat HCV could be as low as $80 in the US BOSTON — In this exclusive video at The Liver Meeting, Andrew M. Hill, PhD,...

Direct-acting antiretrovirals in genotype 1 HCV patients with mental health conditions safe, well tolerated

›
Direct-acting antiretrovirals in genotype 1 HCV patients with mental health conditions safe, well tolerated Publish date: November 18, 2016...
Friday, November 18, 2016

AASLD 2016 Review - Watch Advances in Chronic Hepatitis C: Management and Treatment

›
After each conference this blog links to a series of education-related information on important findings related to ongoing challenge...
Thursday, November 17, 2016

Adding Voxilaprevir to Sofosbuvir/Velpatasvir Effective for HCV Genotype 3: Presented at AASLD

›
A dding Voxilaprevir to Sofosbuvir/Velpatasvir Effective for HCV Genotype 3: Presented at AASLD By Frances Morin BOSTON -- November 1...
Wednesday, November 16, 2016

Coffee Consumption and Herbal Tea Tied to Lower Liver Stiffness

›
Herbal Tea, Coffee Consumption Tied to Lower Liver Stiffness Tea and coffee consumption is ubiquitous around the world. Both contain pol...
Tuesday, November 15, 2016

AbbVie's Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

›
AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients w...

AASLD 2016 Grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) highly effective for hard-to-treat genotype 3 hepatitis C patients

›
HIVandHepatitis conference coverage includes commentary with interim results from ongoing clinical studies by freelance medical writer, edi...

Prometheus HepaStem - Therapeutic alternative to liver transplantation could be on horizon in NASH

›
Nov 11 Therapeutic alternative to liver transplantation could be on horizon in NASH Kris Gellynck, PhD, manager of research and development...

AASLD 2016 Study eyed zinc for slowing progression of chronic liver disease

›
Study eyed zinc for slowing progression of chronic liver disease BOSTON – Oral zinc supplementation was associated with maintenance of li...
Monday, November 14, 2016

AASLD 2016 IFN-free DAA Regimens Found Safe and Effective for Elderly Patients

›
IFN-free DAA Regimens Found Safe and Effective for Elderly Patients By Da Hee Han, PharmD BOSTON, MA—Interferon (IFN)-free dir...
Sunday, November 13, 2016

AASLD 2016 Liver Cancer Rare After HCV Therapy

›
Liver Cancer Rare After HCV Therapy by Michael Smith Michael Smith North American Correspondent, MedPage Today But some patients dev...

AASLD 2016 Glecaprevir/Pibrentasvir: High SVR Rates in HCV GT 2, 4, 5, 6 Without Cirrhosis

›
Nov 13 Glecaprevir/Pibrentasvir: High SVR Rates in HCV GT 2, 4, 5, 6 Without Cirrhosis By Debra Hughes, MS Patients with chronic hepatiti...

AASLD 2016 Once-Daily Simeprevir, AL-335, and Odalasvir Combination Safe, Effective

›
Once-Daily Simeprevir, AL-335, and Odalasvir Combination Safe, Effective By Bryant Furlow November 13, 2016 BOSTON, MA—Once-daily-adm...
Saturday, November 12, 2016

AASLD 2016 Dr. George N. Ioannou on the Efficacy of Antiviral Agents for Hepatitis C in HCC Patients

›
Dr. George N. Ioannou on the Efficacy of Antiviral Agents for Hepatitis C in HCC Patients George N. Ioannou, MD Published O...

AASLD 2016 Biomarkers Define Future Age of Immunotherapy in Cancer

›
Biomarkers Define Future Age of Immunotherapy in Cancer Marilyn White Published Online: Sunday, Nov 13, 2016 The use of ...